Earnings Call Summary | BWX Technologies(BWXT.US) Q1 2024 Earnings Conference
Earnings Call Summary | BWX Technologies(BWXT.US) Q1 2024 Earnings Conference
The following is a summary of the BWX Technologies, Inc. (BWXT) Q1 2024 Earnings Call Transcript:
以下是BWX Technologies, Inc.（BWXT）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
BWX Technologies reported a 6% organic revenue growth and 9% adjusted earnings per share growth in Q1 2024.
The company forecasts full-year mid-single-digit revenue and adjusted EBITDA growth, leading to adjusted earnings per share of $3.05 to $3.20.
BWX Technologies報告稱，2024年第一季度有機收入增長6％，調整後每股收益增長9％。
該公司預測全年中期個位數收入和調整後的息稅折舊攤銷前利潤增長，調整後的每股收益爲3.05美元至3.20美元。
Business Progress:
業務進展：
BWXT is investing $60m to expand and upgrade its Cambridge plant and expects to see a 25% revenue growth for BWXT Medical this year due to strong demand.
Its existing commercial nuclear backlog exceeds $700m, and they have secured a two-year extension for their downblending contract.
The company's microreactor projects for land and sea, including Project Pele, are progressing well, and their drug master file for Lutetium and other APIs is underway.
BWXT is developing its capacity and workforce to sustain higher production rates, having hired 10% of its workforce over the past year.
BWXT正在投資6000萬美元擴建和升級其劍橋工廠，由於需求強勁，預計今年BWXT Medical的收入將增長25％。
其現有的商用核電積壓超過7億美元，他們已確保將稀釋合同延期兩年。
該公司的陸地和海上微反應器項目，包括貝利項目，進展順利，他們的Lutetium和其他原料藥的藥物主文件正在進行中。
BWXT正在發展其產能和員工隊伍，以維持更高的生產率，在過去的一年中僱用了10％的員工。
More details: BWX Technologies IR
更多詳情： BWX 科技 IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。